In contrast, the inability of selective IDO1 inhibitors to effectively inhibit tumor growth in clinical trials highlights the complexity of this pathway and suggests that broader strategies targeting both IDO activity and its interactions with the JAK/STAT and AhR pathways may be necessary for more effective cancer therapies [106]. The gene discussed is AHR; the disease is cancer.